https://www.selleckchem.com/pharmacological_epigenetics.html B-cell lymphoma 6 (BCL6) is a master regulator of germinal center formation that produce antibody-secreting plasma cells and memory B-cells for sustained immune responses. The BTB domain of BCL6 (BCL6BTB) forms a homodimer that mediates transcriptional repression by recruiting its corepressor proteins to form a biologically functional transcriptional complex. The protein-protein interaction (PPI) between the BCL6BTB and its corepressors has emerged as a therapeutic target for the treatment of DLBCL and a number of other human cancers. This Perspective provides an overview of recent advances in the development of BCL6BTB inhibitors from reversible inhibitors, irreversible inhibitors, to BCL6 degraders. Inhibitor design and medicinal chemistry strategies for the development of novel compounds will be provided. The binding mode of new inhibitors to BCL6BTB are highlighted. Also, the in vitro and in vivo assays used for the evaluation of new compounds will be discussed.We studied nonadiabatic dissociation of CS2 from the 1B2 (1Σu+) state using ultrafast extreme ultraviolet photoelectron spectroscopy. A deep UV (200 nm) laser using the filamentation four-wave mixing method and an extreme UV (21.7 eV) laser using the high-order harmonic generation method were employed to achieve the pump-probe laser cross-correlation time of 48 fs. Spectra measured with a high signal-to-noise ratio revealed clear dynamical features of vibrational wave packet motion in the 1B2 state; its electronic decay to lower electronic state(s) within 630 fs; and dissociation into S(1D2), S(3PJ), and CS fragments within 300 fs. The results suggest that both singlet and triplet dissociation occur via intermediate electronic state(s) produced by electronic relaxation from the 1B2 (1Σu+) state.The connection with acute myelogenous leukemia (AML) of dihydroorotate dehydrogenase (hDHODH), a key enzyme in pyrimidine biosynthesis, has attracted sig